Switching therapy after rituximab resistance in AQP4-IgG+ NMOSD shows variable relapse outcomes.
New Hope for Tough-to-Treat Nerve Disorder
This single-center, retrospective case series of 10 adults with AQP4-IgG+ NMOSD who were resistant to rituximab evaluated switching therapy.…
Patients with a rare nerve disease who stopped responding to standard treatment found relief after switching to new therapies that prevented…
FDA Approves Kesimpta (ofatumumab) for Relapsing Forms of Multiple Sclerosis in Adults
The FDA approved a new monthly self-injection drug for multiple sclerosis.
The FDA has approved Kesimpta, a CD20-directed cytolytic antibody, for the treatment of relapsing forms of multiple sclerosis in adults. The…
The FDA approved Kesimpta, a new monthly self-injection for adults with relapsing forms of multiple sclerosis.
Phase 2 trial explores idelalisib plus ofatumumab in untreated CLL/SLL requiring treatment
Can two drugs together help people with untreated blood cancer?
A phase 2 interventional trial evaluated idelalisib plus ofatumumab in 27 previously untreated CLL/SLL patients requiring therapy. The prima…
For people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who need treatment, researchers tested a combinat…